Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
文献类型：期刊论文
| 作者 | Luo, Feng Roger2,3; Ding, Jian4 ; Chen, Helen X.2,5; Liu, Hao6; Fung, Man-Cheong3; Koehler, Maria7; Armand, Jean Pierre8; Jiang, Lei4; Xu, Xiao2,9; Zhang, Ge10
|
| 刊名 | CHINESE JOURNAL OF CANCER
 |
| 出版日期 | 2014-12 |
| 卷号 | 33期号:12页码:620-624 |
| 关键词 | Breakthrough clinical trial cancer medicine |
| ISSN号 | 1000-467X |
| DOI | 10.5732/cjc.014.10246 |
| 文献子类 | Review |
| 英文摘要 | The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the 17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China. |
| WOS关键词 | CELL LUNG-CANCER ; GASTRIC-CANCER ; BREAST-CANCER ; INHIBITOR ; PCI-32765 ; IBRUTINIB |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5312013 |
| WOS记录号 | WOS:000346228500007 |
| 出版者 | SUN YAT SEN UNIV MED SCI WHO |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276813]  |
| 专题 | 药理学第一研究室 |
| 通讯作者 | Luo, Feng Roger |
| 作者单位 | 1.Peking Univ, Beijing Canc Hosp & Inst, Sch Oncol, Beijing 100142, Peoples R China 2.US Chinese Anticanc Assoc, Martinez, CA 94553 USA; 3.Janssen Res & Dev LLC, Dept Oncol, Raritan, NJ 08869 USA; 4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 5.NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA; 6.Novartis Pharmaceut China Oncol, Beijing 10004, Peoples R China; 7.Pfizer Oncol, New York, NY 10017 USA; 8.Inst Gustave Roussy, F-94805 Villejuif, France; 9.ACEA Biosci Inc, San Diego, CA 92121 USA; 10.Jiangsu Hengrui Med Co Ltd, Shanghai 200122, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Luo, Feng Roger,Ding, Jian,Chen, Helen X.,et al. Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J]. CHINESE JOURNAL OF CANCER,2014,33(12):620-624. |
| APA | Luo, Feng Roger.,Ding, Jian.,Chen, Helen X..,Liu, Hao.,Fung, Man-Cheong.,...&Yan, Li.(2014).Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.CHINESE JOURNAL OF CANCER,33(12),620-624. |
| MLA | Luo, Feng Roger,et al."Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting".CHINESE JOURNAL OF CANCER 33.12(2014):620-624. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。